| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
1 Programs in Epidemiology and 2 Biostatistics, and 3 Cancer Prevention Research Program, Fred Hutchinson Cancer Research Center, Seattle, Washington; Departments of 4 Epidemiology and 5 Biostatistics, University of Washington, Seattle, Washington; 6 Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, California; and 7 Swedish Cancer Institute, Seattle, Washington
To examine whether endogenous androgens influence the occurrence of prostate cancer, we conducted a nested case-control study among participants enrolled in the Carotene and Retinol Efficacy Trial. We analyzed serum samples of 300 cases diagnosed between 1987 and 1998, and 300 matched controls. Higher concentrations of testosterone (T) were not associated with increased prostate cancer risk. Relative to men with levels in the lowest fourth of the distribution, men in the upper fourth of total T had a risk of 0.82 [95% confidence interval (CI), 0.52–1.29]. The corresponding relative risks for free T (0.72; 95% CI, 0.45–1.14), percentage of free T (0.74; 95% CI, 0.46–1.19), and total T:sex hormone binding globulin ratio (0.52; 95% CI, 0.32–0.83) similarly were not elevated. Higher concentrations of androstenedione, dehydroepiandrosterone sulfate, and 3
-androstanediol glucuronide were weakly associated with risk. Relative risks associated with being in the highest fourth for androstenedione, dehydroepiandrosterone sulfate, and 3-androstanediol glucuronide were 1.20 (95% CI, 0.76–1.89), 1.38 (95% CI, 0.86–2.21), and 1.27 (95% CI, 0.80–2.00), respectively. Men in the upper fourth of total estradiol (E2), free E2 and percentage of free E2 had relative risks of 0.71 (95% CI, 0.42–1.13), 0.52 (95% CI, 0.33–0.82), and 0.65 (95% CI, 0.40–1.05), respectively. The inverse association between E2 and prostate cancer risk was largely restricted to men with blood collection within 3 years of diagnosis. Our results add to the evidence that serum testosterone is unrelated to prostate cancer incidence. The suggestions that intraprostatic androgen activity may increase risk and that serum estrogens may decrease risk, warrant additional study.
This article has been cited by other articles:
|
|
 |
|
  E. Hormones and Prostate Cancer Collaborative Group Endogenous Sex Hormones and Prostate Cancer: A Collaborative Analysis of 18 Prospective Studies J Natl Cancer Inst, February 6, 2008; 100(3): 170 - 183. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Boger-Megiddo, N. S. Weiss, M. J. Barnett, G. E. Goodman, and C. Chen V89L Polymorphism of the 5{alpha}-Reductase Type II Gene (SRD5A2), Endogenous Sex Hormones, and Prostate Cancer Risk Cancer Epidemiol. Biomarkers Prev., February 1, 2008; 17(2): 286 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Hamilton-Reeves, S. A. Rebello, W. Thomas, J. W. Slaton, and M. S. Kurzer Soy Protein Isolate Increases Urinary Estrogens and the Ratio of 2:16{alpha}-Hydroxyestrone in Men at High Risk of Prostate Cancer J. Nutr., October 1, 2007; 137(10): 2258 - 2263. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Rohrmann, W. G. Nelson, N. Rifai, T. R. Brown, A. Dobs, N. Kanarek, J. D. Yager, and E. A. Platz Serum Estrogen, But Not Testosterone, Levels Differ between Black and White Men in a Nationally Representative Sample of Americans J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2519 - 2525. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Littman, E. White, and A. R. Kristal Anthropometrics and Prostate Cancer Risk Am. J. Epidemiol., June 1, 2007; 165(11): 1271 - 1279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Gong, M. L. Neuhouser, P. J. Goodman, D. Albanes, C. Chi, A. W. Hsing, S. M. Lippman, E. A. Platz, M. N. Pollak, I. M. Thompson, et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 1977 - 1983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Severi, H. A. Morris, R. J. MacInnis, D. R. English, W. Tilley, J. L. Hopper, P. Boyle, and G. G. Giles Circulating Steroid Hormones and the Risk of Prostate Cancer Cancer Epidemiol. Biomarkers Prev., January 1, 2006; 15(1): 86 - 91. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Parsons, H. B. Carter, E. A. Platz, E. J. Wright, P. Landis, and E. J. Metter Serum Testosterone and the Risk of Prostate Cancer: Potential Implications for Testosterone Therapy Cancer Epidemiol. Biomarkers Prev., September 1, 2005; 14(9): 2257 - 2260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Davis, S. L. Davison, S. Donath, and R. J. Bell Circulating Androgen Levels and Self-reported Sexual Function in Women JAMA, July 6, 2005; 294(1): 91 - 96. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H L. BRADLOW and D. W. SEPKOVIC Steroids as Procarcinogenic Agents Ann. N.Y. Acad. Sci., December 1, 2004; 1028(1): 216 - 232. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
